Ignite Creation Date:
2025-12-25 @ 2:49 AM
Ignite Modification Date:
2026-03-07 @ 9:26 PM
Study NCT ID:
NCT02175433
Status:
COMPLETED
Last Update Posted:
2024-11-01
First Post:
2014-06-24
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies
Sponsor:
Astellas Pharma Global Development, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Refractory or relapsed chronic lymphocytic leukemia (CLL) prolymphocytic leukemia (PLL) | View |
| None | Relapsed lymphoid malignancy | View |
| None | Refractory lymphoid malignancy | View |
| None | Pharmacokinetics of AGS67E | View |
| None | hairy cell leukemia (HCL) | View |
| None | AGS67C | View |
| None | non-Hodgkin lymphoma (NHL) | View |
| None | AGS67E | View |